Skip to main content

Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ)

SHZ Healthcare Drug Manufacturers - Specialty & GenericView data quality →
52.2Fair

ValueMarkers Composite Index

Top 42%#25,878 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.28
Low Risk
Altman
44.09
Safe
DCF Value
-
N/A
ROIC
6.3%
Low
P/E
21.7
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ) — VMCI valuation read

000403.SZ prints VMCI 52/100 inside the Healthcare sector, where the median sits at 50. The 2-point above-median delta is the cleanest single-number summary of Pacific Shuanglin Bio-pharmacy Co., Ltd.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On 000403.SZ, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** 000403.SZ trades at 26.0x earnings, 44% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 0.6x leaves covenant headroom; that is the risk line for Pacific Shuanglin Bio-pharmacy Co., Ltd. on the trailing financials.

000403.SZ fell 2.0% over the trailing 7 days, with a -21.3% read on a 30-day basis.

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.

CEO: Xiankui Rong2,635 employeesCNwww.slbiop.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 000403.SZ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.